



Join us

**Arcalyst**  
(rilonacept) For Injection

## **BREAKING THE CYCLE OF RECURRENT PERICARDITIS:** A Targeted Approach for Pain Relief, Inflammation Resolution, and Flare Prevention

**Presented by:**

**Guilherme Oliveira,**

Vice President, Strategy and Concierge Medicine  
Tampa General Hospital

**Wednesday, May 21, 2025 6:15pm ET**

**Jerry's Seafood**

15211 Major Lansdale Blvd  
Bowie, MD 20716

**To register for this program, please contact your Kiniksa Clinical Sales Specialist:**

**Jamila Guyton**

[jguyton@kiniksa.com](mailto:jguyton@kiniksa.com)

**Please RSVP at least 2 days in advance of the program.**

**In accordance with the PhRMA code, Kiniksa cannot purchase  
alcohol for attendees at the speaker programs.**

### **INDICATION**

ARCALYST is indicated for the treatment of recurrent pericarditis (RP) and reduction in risk of recurrence in adults and pediatric patients 12 years and older.

### **IMPORTANT SAFETY INFORMATION**

#### **Warnings and Precautions**

- Interleukin-1 (IL-1) blockade may interfere with the immune response to infections. Treatment with another medication that works through inhibition of IL-1 or inhibition of tumor necrosis factor (TNF) is not recommended as this may increase the risk of serious infection. Serious, life-threatening infections have been reported in patients taking ARCALYST. Do not initiate treatment with ARCALYST in patients with an active or chronic infection.

**Please see additional Important Safety Information continued on next page.**

This educational presentation is sponsored by Kiniksa Pharmaceuticals. It is offered solely for educational purposes. No continuing education credit will be granted. Federal and state law, in addition to industry guidance, limit attendance at this event to only licensed healthcare professionals (HCPs). Family members or guests are not permitted to attend this presentation if they are not an HCP. HCPs with Minnesota or Vermont licenses, or who are employed by Veterans Affairs/DoD will not be offered hospitality due to government restrictions. Please be aware of your limitations prior to attendance as additional restrictions may apply based on state of licensure and institutional affiliations. Kiniksa Pharmaceuticals will report and publicly disclose the costs associated with any meal and/or beverage provided to HCPs as required by law.

**Warnings and Precautions (continued)**

- Discontinue ARCALYST if a patient develops a serious infection.
- It is possible that taking drugs such as ARCALYST that block IL-1 may increase the risk of tuberculosis (TB) or other atypical or opportunistic infections.
- Although the impact of ARCALYST on infections and the development of malignancies is not known, treatment with immunosuppressants, including ARCALYST, may result in an increase in the risk of malignancies.
- Hypersensitivity reactions associated with ARCALYST occurred in clinical trials. Discontinue ARCALYST and initiate appropriate therapy if a hypersensitivity reaction occurs.
- Increases in non-fasting lipid profile parameters occurred in patients treated with ARCALYST in clinical trials. Patients should be monitored for changes in their lipid profiles.
- Since no data are available, avoid administration of live vaccines while patients are receiving ARCALYST. ARCALYST may interfere with normal immune response to new antigens, so vaccines may not be effective in patients receiving ARCALYST. It is recommended that, prior to initiation of therapy with ARCALYST, patients receive all recommended vaccinations, as appropriate.

**Adverse Reactions**

- The most common adverse reactions (≥10%) include injection-site reactions and upper respiratory tract infections.

**Drug Interactions**

- In patients being treated with CYP450 substrates with narrow therapeutic indices, therapeutic monitoring of the effect or drug concentration should be performed, and the individual dose of the medicinal product may need to be adjusted.

Please see full Prescribing Information at [ARCALYST.com/PI](https://www.arcalyst.com/PI) or scan the QR code.



Please visit [ARCALYST.com/HCP](https://www.arcalyst.com/HCP) for more information.

